Fatal liver disease despite sustained eradication of recurrent hepatitis C virus requiring liver retransplantation

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Liver retransplantation for recurrent hepatitis C is usually not recommended for patients with early, severe disease. As it is difficult to predict which patients are at risk, interferon-based therapies are often used after histological confirmation of recurrent disease. Unfortunately, this treatment is poorly tolerated, costly and often unsuccessful. Three patients are described who developed decompensated cirrhosis requiring retransplantation despite sustained viral eradication. With the exception of one patient who developed post transplant nonalcoholic steatohepatitis, no etiology was identified in the others. All were retransplanted and remain hepatitis C negative at a mean follow-up of 25.6 months. Despite a lack of alternatives, the reflexive urge to use interferon-based therapy for recurrent hepatitis C in an attempt to prevent retransplantation at all costs should be resisted, particularly as recent studies suggest onset of recurrent disease after initial transplant does not predict onset of recurrence following retransplantation.

Original languageEnglish
Pages (from-to)286-288
Number of pages3
JournalTransplantation
Volume82
Issue number2
DOIs
StatePublished - Jul 2006
Externally publishedYes

Fingerprint

Hepacivirus
Liver Diseases
Hepatitis C
Liver
Interferons
Transplants
Fibrosis
Therapeutics
Costs and Cost Analysis
Recurrence

All Science Journal Classification (ASJC) codes

  • Transplantation
  • Immunology

Cite this

Fatal liver disease despite sustained eradication of recurrent hepatitis C virus requiring liver retransplantation. / Mukherjee, Sandeep.

In: Transplantation, Vol. 82, No. 2, 07.2006, p. 286-288.

Research output: Contribution to journalArticle

@article{ecc29b7dec5c4313af7cf9f97c46b63c,
title = "Fatal liver disease despite sustained eradication of recurrent hepatitis C virus requiring liver retransplantation",
abstract = "Liver retransplantation for recurrent hepatitis C is usually not recommended for patients with early, severe disease. As it is difficult to predict which patients are at risk, interferon-based therapies are often used after histological confirmation of recurrent disease. Unfortunately, this treatment is poorly tolerated, costly and often unsuccessful. Three patients are described who developed decompensated cirrhosis requiring retransplantation despite sustained viral eradication. With the exception of one patient who developed post transplant nonalcoholic steatohepatitis, no etiology was identified in the others. All were retransplanted and remain hepatitis C negative at a mean follow-up of 25.6 months. Despite a lack of alternatives, the reflexive urge to use interferon-based therapy for recurrent hepatitis C in an attempt to prevent retransplantation at all costs should be resisted, particularly as recent studies suggest onset of recurrent disease after initial transplant does not predict onset of recurrence following retransplantation.",
author = "Sandeep Mukherjee",
year = "2006",
month = "7",
doi = "10.1097/01.tp.0000226178.71720.43",
language = "English",
volume = "82",
pages = "286--288",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Fatal liver disease despite sustained eradication of recurrent hepatitis C virus requiring liver retransplantation

AU - Mukherjee, Sandeep

PY - 2006/7

Y1 - 2006/7

N2 - Liver retransplantation for recurrent hepatitis C is usually not recommended for patients with early, severe disease. As it is difficult to predict which patients are at risk, interferon-based therapies are often used after histological confirmation of recurrent disease. Unfortunately, this treatment is poorly tolerated, costly and often unsuccessful. Three patients are described who developed decompensated cirrhosis requiring retransplantation despite sustained viral eradication. With the exception of one patient who developed post transplant nonalcoholic steatohepatitis, no etiology was identified in the others. All were retransplanted and remain hepatitis C negative at a mean follow-up of 25.6 months. Despite a lack of alternatives, the reflexive urge to use interferon-based therapy for recurrent hepatitis C in an attempt to prevent retransplantation at all costs should be resisted, particularly as recent studies suggest onset of recurrent disease after initial transplant does not predict onset of recurrence following retransplantation.

AB - Liver retransplantation for recurrent hepatitis C is usually not recommended for patients with early, severe disease. As it is difficult to predict which patients are at risk, interferon-based therapies are often used after histological confirmation of recurrent disease. Unfortunately, this treatment is poorly tolerated, costly and often unsuccessful. Three patients are described who developed decompensated cirrhosis requiring retransplantation despite sustained viral eradication. With the exception of one patient who developed post transplant nonalcoholic steatohepatitis, no etiology was identified in the others. All were retransplanted and remain hepatitis C negative at a mean follow-up of 25.6 months. Despite a lack of alternatives, the reflexive urge to use interferon-based therapy for recurrent hepatitis C in an attempt to prevent retransplantation at all costs should be resisted, particularly as recent studies suggest onset of recurrent disease after initial transplant does not predict onset of recurrence following retransplantation.

UR - http://www.scopus.com/inward/record.url?scp=33746397487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746397487&partnerID=8YFLogxK

U2 - 10.1097/01.tp.0000226178.71720.43

DO - 10.1097/01.tp.0000226178.71720.43

M3 - Article

VL - 82

SP - 286

EP - 288

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 2

ER -